Deprenyl and the Issue of Neuroprotection

Vingerhoets, François; Uitti, Ryan J.; Calne, Donald B.

doi:10.1159/000116999

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These “washout” periods also represent a limitation in most clinical trials, because it is very difficult and ethically questionable to plan a long period without symptomatic relief in an advanced PD patient. In addition, the length of the washout could raise some technical criticism: the residual effect or “carry-over effect” of the symptomatic drug treatment it is often very difficult to separate from potential neuroprotection [ 128 ].…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective Surgical Strategies in Parkinson’s Disease: Role of Preclinical Data

Torres

Molet

Moro

et al. 2017

IJMS

View full text Add to dashboard Cite

Although there have been many pharmacological agents considered to be neuroprotective therapy in Parkinson’s disease (PD) patients, neurosurgical approaches aimed to neuroprotect or restore the degenerative nigrostriatal system have rarely been the focus of in depth reviews. Here, we explore the neuroprotective strategies involving invasive surgical approaches (NSI) using neurotoxic models 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), which have led to clinical trials. We focus on several NSI approaches, namely deep brain stimulation of the subthalamic nucleus, glial neurotrophic derived factor (GDNF) administration and cell grafting methods. Although most of these interventions have produced positive results in preclinical animal models, either from behavioral or histological studies, they have generally failed to pass randomized clinical trials to validate each approach. We argue that NSI are promising approaches for neurorestoration in PD, but preclinical studies should be planned carefully in order not only to detect benefits but also to detect potential adverse effects. Further, clinical trials should be designed to be able to detect and disentangle neuroprotection from symptomatic effects. In summary, our review study evaluates the pertinence of preclinical models to study NSI for PD and how this affects their efficacy when translated into clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%